Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Marginal Zone Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non-Hodgkin’s Lymphoma (1038
)
Diffuse Large B Cell Lymphoma (364
)
Mantle Cell Lymphoma (126
)
T Cell Non-Hodgkin Lymphoma (118
)
Small Lymphocytic Lymphoma (106
)
Follicular Lymphoma (85
)
Peripheral T-cell Lymphoma (71
)
Lymphoplasmacytic Lymphoma (64
)
Burkitt Lymphoma (20
)
Cutaneous T-cell Lymphoma (19
)
Mediastinal B Cell Lymphoma (10
)
Non-Hodgkin’s Lymphoma (1038
)
Diffuse Large B Cell Lymphoma (364
)
Mantle Cell Lymphoma (126
)
T Cell Non-Hodgkin Lymphoma (118
)
Small Lymphocytic Lymphoma (106
)
Follicular Lymphoma (85
)
Peripheral T-cell Lymphoma (71
)
Lymphoplasmacytic Lymphoma (64
)
Burkitt Lymphoma (20
)
Cutaneous T-cell Lymphoma (19
)
Mediastinal B Cell Lymphoma (10
)
›
Associations
(41)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
umbralisib
Sensitive: A1 - Approval
umbralisib
Sensitive
:
A1
umbralisib
Sensitive: A1 - Approval
umbralisib
Sensitive
:
A1
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
rituximab
Sensitive: A2 - Guideline
rituximab
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
axicabtagene ciloleucel
Sensitive: A2 - Guideline
axicabtagene ciloleucel
Sensitive
:
A2
axicabtagene ciloleucel
Sensitive: A2 - Guideline
axicabtagene ciloleucel
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
obinutuzumab
Sensitive: A2 - Guideline
obinutuzumab
Sensitive
:
A2
obinutuzumab
Sensitive: A2 - Guideline
obinutuzumab
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
idelalisib
Sensitive: A2 - Guideline
idelalisib
Sensitive
:
A2
idelalisib
Sensitive: A2 - Guideline
idelalisib
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
duvelisib
Sensitive: A2 - Guideline
duvelisib
Sensitive
:
A2
duvelisib
Sensitive: A2 - Guideline
duvelisib
Sensitive
:
A2
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
copanlisib
Sensitive: A2 - Guideline
copanlisib
Sensitive
:
A2
copanlisib
Sensitive: A2 - Guideline
copanlisib
Sensitive
:
A2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.